osimertinib
astrazeneca
['osimertinib']
adjuvant osimertinib. robust dfs improvement. hr 0.23 but is it cure or just delay in progression.? we need to wait for 2023 for os data #esmo22 (tweet + snapshots courtesy- ) 
A  peer-reviewed international journal published by the Indian Society of Medical and Paediatric oncology
https://t.co/Kk66CvDpOJ